Blood coagulation factor X activating enzyme and application thereof
Patent Information
- Application Number
- CN202380033433.4
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2022-04-14
- Filing Date
- 2023-04-14
- Publication Date
- 2024-12-06
AI Technical Summary
The existing methods for extracting and preparing coagulation factor
Provides a new coagulation factor purity and activity, and reduce production costs.
The preparation of high-purity and high-activity coagulation factor
Smart Images

Figure 00000042_0000 
Figure 00000042_0001 
Figure 00000043_0000
Abstract
Description
A coagulation factor X activating enzyme and its application Technical Field
[0001] The present invention belongs to the technical field of biomedicine, and in particular relates to a coagulation factor X activating enzyme and an application thereof. Background Art
[0002] The human coagulation mechanism is a highly complex and delicate process. Twelve factors have been identified as participating in coagulation. Among them, coagulation factor X (FX) is a crucial component of the coagulation system. Coagulation factor X (FX) is a vitamin K-dependent serine protease. Its active form (FXa) is the sole physiological activator of prothrombin in the body and plays a key role in the common coagulation pathway. Factor X activating enzymes specifically activate FX, exposing the active site to generate FXa. FXa then forms a prothrombin complex with activated platelets, FVa, and calcium ions at the site of injury, thereby increasing thrombin generation. Thrombin activates platelets and fibrinogens V and VIII at the site of injury and forms a hemostatic plug by converting fibrinogen to fibrin, achieving hemostasis in patients with bleeding. This promising application has enormous potential in treating surgical wound bleeding, internal bleeding disorders, and coagulation disorders such as hemophilia.
[0003] The earliest discovered and most active factor X activator (RVV-X) was extracted from the venom of the Russel's viper (Daboia russelii siamensis). RVV-X is a metalloprotease composed of a heavy chain (α chain, molecular weight 57,600 Da) and two light chains (β chain, molecular weight 19,400 Da, and γ chain, molecular weight 16,400 Da) linked by disulfide bonds. The heavy chain contains the catalytic domain, while the light chain is homologous to C-type lectins and plays a regulatory role in the calcium-dependent activation of factor X activator. During its synthesis in vivo, RVV-X undergoes a series of post-translational modifications, such as glycosylation, which may affect its enzymatic activity.
[0004] Various methods are available in the prior art for extracting or preparing factor X activating enzymes from Vipera rotundus. For example, Kisiel et al. subjected Vipera rotundus venom to Sephadex G-150 molecular sieve chromatography, QAE-Sephadex A-50 anion chromatography, and Sephadex G-25 molecular sieve chromatography to obtain two types of factor X activating enzymes. Under non-reducing conditions, RVV-X exhibited molecular weights of 90,000 and 79,000, respectively. CN101104847A sequentially subjected Vipera rotundus venom to DEAE-Sephadex A-50 anion chromatography, dialysis, cellulose DEAE-32 anion chromatography, and gel filtration chromatography to obtain a new factor X activating enzyme. CN1096523988A sequentially subjected Vipera rotundus venom to molecular sieve chromatography and weak cationic chromatography to obtain factor X activating enzymes with molecular weights of 79 kD and 98 kD, respectively.
[0005] The present invention provides a novel factor X activating enzyme from Vipera rotundus venom. Furthermore, the present invention provides a method for extracting factor X activating enzyme, which produces a product of high purity and activity, significantly improving its yield, and facilitating large-scale industrial production. The technical solution of the present invention is of great significance for hemostasis or the treatment of bleeding disorders.
[0006] Summary of the Invention
[0007] Factor X activating enzyme
[0008] In one aspect, the present invention provides a novel factor X activating enzyme, comprising three polypeptide chains: α, β, and γ. The amino acid sequence of the α chain is shown in SEQ ID NO: 8, the amino acid sequence of the β chain is shown in SEQ ID NO: 10, and the amino acid sequence of the γ chain is shown in SEQ ID NO: 12.
[0009] In some embodiments, the α, β, and / or γ polypeptide chains are modified with glycosylation.
[0010] In some embodiments, the α, β and / or γ polypeptide chain amino acid sequence is covalently linked to an N-glycan on at least one amino acid residue.
[0011] In some embodiments, the amino acid residue is an asparagine (Asn) residue.
[0012] The asparagine (Asn) residue is selected from one or more of the following:
[0013] α chain: Asn28, Asn69, Asn163, Asn183;
[0014] β chain: Asn59; and / or
[0015] γ chain: Asn24.
[0016] In some embodiments, the coagulation factor X activating enzyme:
[0017] The N-glycans at Asn28 in the α chain include: A2BG2S2, FA2BG2S2, F2A2BG2S2, and A3BG3S3;
[0018] and / or,
[0019] The N-glycans at Asn69 in the α chain include: FA2S2, A2S2, FA3G2S2, A3G2S2, A4G3S3, and A3S3;
[0020] and / or,
[0021] The N-glycans at Asn163 in the α chain include: FA2G2S2, A2BG2S2, FA2BG2S2, F2A2BG2S2, A3G3S3, FA3G3S3, A3BG3S3, and FA3BG3S3;
[0022] and / or,
[0023] The N-glycans at Asn183 in the α chain include: A2G2S1, A2G2S1M4, A2BG1S1, FA2BG1S1, A2BG2S2, FA2BG2S2, and M5;
[0024] and / or,
[0025] The N-glycans at the Asn59 position in the β chain include: A2BG2S2, FA2BG2S2, F2A2BG2S2, A3BG3S3, and further include N-glycans with a galactose terminal end. Preferably, the N-glycans with a galactose terminal end include: A2BG2S1, FA3G3S2, etc.;
[0026] and / or,
[0027] The N-glycans at the Asn24 site in the γ chain include: A2BG1S1, FA2BG1S1, FA2BG2S1, A2BG2S2, FA2BG2S2, F2A2BG2S2, and further include tri-antennary or tetra-antennary branched N-glycans with fucosyl and / or acetylated sialic acid. Preferably, the tri-antennary or tetra-antennary branched N-glycans include FA3G3S2, FA3BG3S3, A3BG2S2, A3BG3S3, etc.
[0028] In some embodiments, the factor X activating enzyme:
[0029] The N-glycans at Asn28 in the α chain include:
[0030] A2BG2S2, the relative content of which is 22-32%, preferably 25-30%, more preferably 25%, 25.5%, 26%, 26.5%, 27%, 27.5%, 28%, 28.5%, 29%, 29.5% or 30%;
[0031] FA2BG2S2, the relative content of which is 30-40%, preferably 34-38%, more preferably 34%, 34.5%, 35%, 35.5%, 36%, 36.5%, 37%, 37.5% or 38%;
[0032] F2A2BG2S2, the relative content of which is 18-28%, preferably 20-25%, more preferably 20%, 20.5%, 21%, 21.5%, 22%, 22.5%, 23%, 23.5%, 24%, 24.5% or 25%; and
[0033] A3BG3S3, the relative content of which is 5-10%, preferably 6-9%; more preferably 6%, 6.5%, 7%, 7.5%, 8%, 8.5% or 9%;
[0034] and / or,
[0035] The N-glycans at Asn69 in the α chain include:
[0036] FA2S2, the relative content of which is 5-10%, preferably 6-9%, more preferably 6%, 6.5%, 7%, 7.5%, 8%, 8.5% or 9%;
[0037] A2S2, the relative content of which is 5-10%, preferably 6-8%, more preferably 6%, 6.5%, 7%, 7.5% or 8%;
[0038] FA3G2S2, the relative content of which is 7-20%, preferably 9-15%, more preferably 9%, 9.5%, 10%, 10.5%, 11%, 11.5%, 12%, 12.5%, 13%, 13.5%, 14%, 14.5% or 15%;
[0039] A3G2S2, the relative content of which is 20-30%, preferably 22-29%, more preferably 22%, 22.5%, 23%, 23.5%, 24%, 24.5%, 25%, 25.5%, 26%, 26.5%, 27%, 27.5%, 28%, 28.5% or 29%;
[0040] A4G3S3, the relative content of which is 10-25%, preferably 15-20%, more preferably 15%, 15.5%, 16%, 16.5%, 17%, 17.5%, 18%, 18.5%, 19%, 19.5% or 20%; and
[0041] A3S3, the relative content of which is 15-30%, preferably 16-20%, more preferably 16%, 16.5%, 17%, 17.5%, 18%, 18.5%, 19%, 19.5% or 20%;
[0042] and / or,
[0043] The N-glycans at Asn163 in the α chain include:
[0044] FA2G2S2, the relative content of which is 3-8%, preferably 4-6%, more preferably 4%, 4.5%, 5%, 5.5% or 6%;
[0045] A2BG2S2, the relative content of which is 6-12%, preferably 8-10%, more preferably 8%, 8.5%, 9%, 9.5% or 10%;
[0046] FA2BG2S2, the relative content of which is 15-25%, preferably 19-22%, more preferably 19%, 19.5%, 20%, 20.5%, 21%, 21.5% or 22%;
[0047] F2A2BG2S2, the relative content of which is 10-25%, preferably 15-20%, more preferably 15%, 15.5%, 16%, 16.5%, 17%, 17.5%, 18%, 18.5%, 19%, 19.5% or 20%;
[0048] A3G3S3, the relative content of which is 5-10%, preferably 7-9%, more preferably 7%, 7.5%, 8%, 8.5% or 9%;
[0049] FA3G3S3, the relative content of which is 5-10%, preferably 8-9%, more preferably 8%, 8.5% or 9%;
[0050] A3BG3S3, the relative content of which is 5-10%, preferably 7-9%, more preferably 7%, 7.5%, 8%, 8.5% or 9%; and
[0051] FA3BG3S3, the relative content of which is 3-10%, preferably 5-8%; more preferably 5%, 5.5%, 6%, 6.5%, 7%, 7.5% or 8%;
[0052] and / or,
[0053] The N-glycans at Asn183 in the α chain include:
[0054] A2G2S1, the relative content of which is 5-15%, preferably 9-10%, more preferably 9%, 9.5% or 10%;
[0055] A2G2S1M4, the relative content of which is 4-8%, preferably 5-6%, more preferably 5%, 5.5% or 6%;
[0056] A2BG1S1, the relative content of which is 10-17%, preferably 12-14%, more preferably 12%, 12.5%, 13%, 13.5% or 14%;
[0057] FA2BG1S1, the relative content of which is 5-10%, preferably 7-8%, more preferably 7%, 7.5% or 8%;
[0058] A2BG2S2, the relative content of which is 10-20%, preferably 14-16%, more preferably 14%, 14.5%, 15%, 15.5%, 16%;
[0059] FA2BG2S2, the relative content of which is 6-12%, preferably 8-10%, more preferably 8%, 8.5%, 9%, 9.5% or 10%; and
[0060] M5, its relative content is 3-8%, preferably 4-7%; more preferably 4%, 4.5%, 5%, 5.5%, 6%, 6.5% or 7%;
[0061] and / or,
[0062] The N-glycans at Asn59 in the β chain include:
[0063] A2BG2S2, the relative content of which is 15-25%, preferably 19-24%, more preferably 19%, 19.5%, 20%, 20.5%, 21%, 21.5%, 22%, 22.5%, 23%, 23.5% or 24%;
[0064] FA2BG2S2, the relative content of which is 30-40%, preferably 32-34%, more preferably 32%, 32.5%, 33%, 33.5% or 34%;
[0065] F2A2BG2S2, the relative content of which is 20-30%, preferably 21-27%, more preferably 21%, 21.5%, 22%, 22.5%, 23%, 23.5%, 24%, 24.5%, 25%, 25.5%, 26%, 26.5% or 27%;
[0066] A3BG3S3, the relative content of which is 3-10%; preferably 5-7%, more preferably 5%, 5.5%, 6%, 6.5% or 7%;
[0067] N-glycans with galactose terminal end, the relative content of which is 1-5%, preferably 2-4%, more preferably 2%, 2.5%, 3%, 3.5% or 4%;
[0068] and / or,
[0069] The N-glycans at Asn24 in the γ chain include:
[0070] A2BG1S1, its relative content is 4-10%, preferably 6-8%, more preferably 6%, 6.5%, 7%, 7.5% or 8%; FA2BG1S1, its relative content is 20-30%, preferably 24-28%, more preferably 24%, 24.5%, 25%, 25.5%, 26%, 26.5%, 27%, 27.5% or 28%;
[0071] FA2BG2S1, the relative content of which is 3-8%, preferably 5-7%, more preferably 5%, 5.5%, 6%, 6.5% or 7%;
[0072] A2BG2S2, the relative content of which is 9-18%, preferably 11-14%, more preferably 11%, 11.5%, 12%, 12.5%, 13%, 13.5% or 14%;
[0073] FA2BG2S2, the relative content of which is 20-30%, preferably 25-28%, more preferably 25%, 25.5%, 26%, 26.5%, 27%, 27.5% or 28%;
[0074] F2A2BG2S2, the relative content of which is 4-10%, preferably 6-8%, more preferably 6%, 6.5%, 7%, 7.5% or 8%;
[0075] The relative content of tri-antennary or tetra-antennary branched N-glycans with fucosyl and acetylated sialic acid is 5-12%, preferably 6-10%, and further preferably 6%, 6.5%, 7%, 7.5%, 8%, 8.5%, 9%, 9.5% or 10%.
[0076] In some embodiments, the relative content of N-glycans refers to the percentage of factor X activating enzyme molecules containing a specific N-glycan at a certain site to the total number of factor X activating enzyme molecules.
[0077] In some embodiments, the coagulation factor X activating enzyme is derived from Daboia russelii siamensis. In some specific embodiments, the coagulation factor X activating enzyme is extracted from the venom of Daboia russelii siamensis or prepared by genetic engineering.
[0078] In another aspect, the present invention provides a pharmaceutical composition comprising the aforementioned factor X activating enzyme and a pharmaceutically acceptable carrier. The pharmaceutical composition of the present invention can be obtained by mixing factor X activating enzyme of a desired purity with an optional pharmaceutically acceptable carrier, excipient, or stabilizer. Furthermore, the pharmaceutical composition of the present invention can be prepared as a lyophilized formulation or a liquid formulation.
[0079] The pharmaceutical compositions of the present invention may also contain one or more other active substances necessary to treat a specific condition, preferably substances with complementary activities and no adverse reactions with each other. For example, in addition to factor X activating enzyme, it may be desirable to further include other active pharmaceutical ingredients that can stop bleeding or promote blood coagulation. These ingredients are combined in amounts effective for their intended purpose. The effective amount of these other ingredients depends on the amount of factor X activating enzyme in the composition, the type of disease or condition or treatment being treated, and other factors as described herein.
[0080] In another aspect, the present invention provides a method for stopping bleeding or treating a bleeding disease, comprising administering a therapeutically effective amount of the aforementioned factor X activating enzyme or the aforementioned pharmaceutical composition to a subject in need thereof.
[0081] In another aspect, the present invention provides use of the aforementioned factor X activating enzyme or a pharmaceutical composition comprising the aforementioned factor X activating enzyme in the preparation of a medicament for hemostasis or treatment of bleeding diseases.
[0082] In some embodiments, the bleeding disorder includes surgical wound bleeding, medical bleeding disorder, hereditary bleeding disorder or coagulation system disease; in some embodiments, the coagulation system disease includes hemophilia; in some embodiments, the hemophilia is hemophilia with inhibitors; in some embodiments, the hemophilia is hemophilia A or hemophilia B.
[0083] The factor X activating enzyme of the present invention or a pharmaceutical composition thereof can be administered to an individual (e.g., a human) by a variety of routes, including, for example, intravenous injection, intraarterial administration, intraperitoneal injection, intrapulmonary administration, oral administration, inhalation administration, intravascular administration, intramuscular injection, intratracheal administration, subcutaneous injection, intraocular administration, intrathecal administration, mucosal administration, or transdermal administration.
[0084] Factor X activating enzyme or its pharmaceutical composition for in vivo administration must be sterile. This can be easily achieved, for example, by filtration through a sterile filtration membrane.
[0085] In another aspect, the present invention also provides an article of manufacture and / or kit. Preferably, the article of manufacture and / or kit may include a container and a label or package insert on or accompanying the container. Suitable containers include, for example, bottles, vials, syringes, etc. The container can be made of a variety of materials, such as glass or plastic. Typically, the container contains a pharmaceutical composition that is effective for stopping bleeding or treating a bleeding disorder and has a sterile port (for example, the container may be an intravenous infusion bag or a vial with a lid pierceable by a hypodermic needle). At least one active substance in the pharmaceutical composition is the factor X activating enzyme described herein. The label or package insert indicates that the composition can be used to stop bleeding or treat a bleeding disorder. A package insert is an instruction sheet typically included in commercial packaging for therapeutic products that contains indications, usage, dosage, route of administration, contraindications, and / or warnings related to the use of these therapeutic products. In addition, the article of manufacture and / or kit may also include a second container containing a pharmaceutically acceptable buffer, such as bacteriostatic water for injection (BWFI), phosphate-buffered saline, Ringer's solution, or dextrose solution. Other materials desirable from a commercial and user perspective may also be included, including other buffers, diluents, filters, needles, and syringes.
[0086] In another aspect, the present invention also provides an isolated nucleic acid molecule encoding the above-mentioned factor X activating enzyme.
[0087] In another aspect, the present invention also provides a vector comprising the above-mentioned nucleic acid molecule. In some embodiments, the vector is a DNA vector. In some embodiments, the vector is a prokaryotic expression vector or a eukaryotic expression vector.
[0088] Also provided are methods for inserting the nucleic acid molecules of the present invention into vectors. In one embodiment of the present invention, a natural or synthetic nucleic acid encoding factor X activating enzyme is inserted into a suitable expression vector such that the nucleic acid is operably linked to 5' and 3' regulatory elements, such as a promoter and a 3' untranslated region (UTR), to express factor X activating enzyme. The vector is suitable for replication and integration in prokaryotic and / or eukaryotic host cells. Typical cloning and expression vectors contain transcriptional and translational terminators, initiation sequences, and promoters to regulate expression of the target nucleic acid sequence. The vector may also contain one or more selectable marker genes and other genetic elements. An example of a suitable promoter is the immediate early cytomegalovirus (CMV) promoter sequence. This promoter sequence is a strong constitutive promoter sequence that can drive high-level expression of any polynucleotide sequence operably linked to it. Another example of a suitable promoter is the elongation factor 1α (EF-1α) promoter. However, other constitutive promoters may also be used, including but not limited to the simian virus 40 (SV40) early promoter, mouse mammary tumor virus (MMTV), human immunodeficiency virus long terminal repeat (HIV-LTR) promoter, MoMuLV promoter, avian leukosis virus promoter, Epstein-Barr virus immediate early promoter, Rous sarcoma virus promoter, and human gene promoters, such as but not limited to the actin promoter, myosin promoter, hemoglobin promoter, and creatine kinase promoter. In addition, inducible promoters are also considered part of the invention. The use of inducible promoters provides a molecular switch that can activate the expression of a polynucleotide sequence operably linked thereto when such expression is desired, and turn off expression when it is not desired. Inducible promoters include, but are not limited to, metallothionein promoters, glucocorticoid promoters, progesterone promoters, and tetracycline promoters.
[0089] In another aspect, the present invention also provides an isolated host cell comprising the aforementioned factor X activating enzyme, a factor X activating enzyme nucleic acid molecule, or a vector. In some embodiments, the host cell is a prokaryotic cell or a eukaryotic cell. In some embodiments, the prokaryotic cell is an Escherichia coli cell.
[0090] Methods for introducing nucleic acid molecules or vectors into cells and expressing them are known in the art. Vectors can be readily introduced into host cells by any method known in the art, for example, by physical, chemical, or biological methods. Physical methods for introducing polynucleotides into host cells include calcium phosphate precipitation, lipofection, biolistic methods, microinjection, electroporation, and the like. Methods for preparing cells containing vectors and / or exogenous nucleic acids are well known in the art. In some embodiments, polynucleotides are introduced into host cells by calcium phosphate transfection. Biological methods for introducing target polynucleotides into host cells include the use of DNA and RNA vectors. Viral vectors, particularly retroviral vectors, have become the most widely used method for inserting genes into mammalian cells, such as human cells. Other viral vectors can be derived from lentiviruses, poxviruses, herpes simplex virus type 1, adenoviruses, and adeno-associated viruses, among others. Chemical methods for introducing polynucleotides into host cells include colloidal dispersion systems, such as polymer complexes, nanocapsules, microspheres, magnetic beads, and lipid-based systems, including oil-in-water emulsions, micelles, mixed micelles, and liposomes. An exemplary colloidal system used as a delivery vehicle in vivo and in vitro is the liposome (eg, an artificial membrane vesicle).
[0091] To confirm the presence of a recombinant DNA sequence in a host cell, various experiments can be performed. Such experiments include, for example, "molecular biology" experiments well known to those skilled in the art, such as Southern and Northern blotting, RT-PCR, and PCR; and "biochemical" experiments, such as detecting the presence or absence of a particular polypeptide, such as by immunological methods (ELISAs and Western blots), all of which fall within the scope of the present invention.
[0092] In one aspect, the present invention further provides a method for preparing the above-mentioned coagulation factor X activating enzyme, the method comprising the following steps:
[0093] a) culturing the host cell under conditions that effectively express factor X activating enzyme;
[0094] b) obtaining the expressed factor X activating enzyme from the host cells.
[0095] In another aspect, the present invention also provides a method for glycosylation modification of the aforementioned factor X activating enzyme, comprising genetically engineering a host cell to produce factor X activating enzyme having a predetermined N-glycosylation modification, and / or treating the factor X activating enzyme with a glycosylation-related enzyme to impart the predetermined N-glycosylation modification.
[0096] In another aspect, the present invention also provides a method for preparing the above-mentioned coagulation factor X activating enzyme, the method comprising the following steps:
[0097] a) obtaining a stock solution of Vipera venom;
[0098] b) separating and purifying the snake venom stock solution to obtain the aforementioned coagulation factor X activating enzyme.
[0099] Method for preparing and extracting coagulation factor X activating enzyme
[0100] In one aspect of the present invention, a method for extracting factor X activating enzyme from Vipera rotundus is provided, the method comprising the following steps in sequence:
[0101] (a) obtaining a sample of Vipera viper venom;
[0102] (b) subjecting the sample to anion exchange chromatography;
[0103] (c) After the anion exchange chromatography purification is completed, the sample is subjected to cation exchange chromatography;
[0104] (d) Obtaining factor X activating enzyme.
[0105] In some preferred embodiments, the anion exchange chromatography and the cation exchange chromatography are each performed only once.
[0106] In other preferred embodiments, no other purification steps are performed after the cation exchange chromatography, or a molecular sieve chromatography step is further included after the cation exchange chromatography, and no other purification steps are performed.
[0107] Anion exchange chromatography
[0108] In some embodiments, the chromatography column filler medium of the anion exchange chromatography is agarose or a polymer;
[0109] Preferably, the chromatography column with agarose as filler is selected from Sepharose HP, Sepharose FF, Capto, or Diamond, more preferably Q Sepharose HP, Q Sepharose FF, Capto Q, EDAE-Sepharose FF, Diamond Q or Diamond MIX-A;
[0110] Preferably, the filler is a polymer medium such as polystyrene / phenylene divinyl, polyacrylate or diethylaminoethyl; preferably, the chromatography column is NenoGel 50Q, UniGel 65Q HC or UniGel 30DEAE.
[0111] In some embodiments, the eluent of the anion exchange chromatography is a Tris-HCl buffer containing NaCl with a pH value of 8.0-8.6, wherein the concentration of the Tris-HCl buffer is 10 mM-30 mM and the concentration of NaCl is 0.1 M-0.5 M;
[0112] Preferably, the pH value of the Tris-HCl buffer is 8.0, 8.1, 8.2, 8.3, 8.4, 8.5 or 8.6, the concentration of the Tris-HCl buffer is 10 mM, 15 mM, 20 mM, 25 mM or 30 mM; the concentration of NaCl is 0.1 M, 0.2 M, 0.3 M, 0.4 M or 0.5 M;
[0113] Preferably, the elution flow rate of the anion exchange column chromatography is 30 cm / hour to 150 cm / hour, preferably 80 cm / hour to 120 cm / hour, more preferably 90 cm / hour.
[0114] Cation exchange chromatography
[0115] In some embodiments, the cation exchange chromatography column filler medium is agarose or a polymer;
[0116] Preferably, the chromatography column whose filler medium is agarose is selected from Capto SP ImpRes, CM Beads 6FF or Diamond MMC;
[0117] Preferably, the polymer medium is polystyrene / styrene; preferably, the chromatography column is NenoGel50SP.
[0118] In some embodiments, the cation exchange chromatography eluent is a phosphate buffer containing NaCl with a pH value of 6.5-7.5, wherein the concentration of the phosphate buffer is 10 mM-30 mM and the concentration of NaCl is 0.2 M-0.6 M;
[0119] Preferably, the pH value of the phosphate buffer is 6.5, 6.7, 6.8, 6.9, 7.0, 7.2 or 7.5, the concentration of the phosphate buffer is 10 mM, 15 mM, 20 mM, 25 mM or 30 mM; the concentration of NaCl is 0.2 M, 0.3 M, 0.4 M, 0.5 M or 0.6 M;
[0120] Preferably, the elution flow rate of the cation exchange column chromatography is 30 cm / hour to 150 cm / hour, preferably 40 cm / hour to 100 cm / hour, more preferably 60 cm / hour.
[0121] Purification steps prior to anion exchange chromatography
[0122] In some embodiments, before the anion exchange chromatography, molecular sieve chromatography, heparin affinity chromatography or hydrophobic chromatography may be further included.
[0123] Molecular sieve chromatography
[0124] In some embodiments, the molecular sieve chromatography column filler is selected from gel filtration media, preferably Sephacryl, Superdex or Sephadex; more preferably Sephacryl S-200HR, Superdex75pg, Superdex200pg or SephadexG25;
[0125] Preferably, the eluent of the molecular sieve is a Tris-HCl buffer with a pH value of 8.0-8.6, and the concentration of the Tris-HCl buffer is 10mM-30mM; preferably, the pH value of the Tris-HCl buffer is 8.0, 8.1, 8.2, 8.3, 8.4, 8.5 or 8.6, and the concentration is 10mM, 15mM, 20mM, 25mM or 30mM;
[0126] Preferably, the elution flow rate of the molecular sieve chromatography is 30 cm / hour to 150 cm / hour, preferably 40 cm / hour to 120 cm / hour, more preferably 60 cm / hour.
[0127] Heparin affinity chromatography
[0128] In some embodiments, the chromatography column filler for heparin affinity chromatography is selected from agarose medium; preferably Capto heparin, Heparin Berpharose FF, Heparin Sepharose 6F.F., Heparin Sepharose HP;
[0129] Preferably, the eluent of the heparin affinity chromatography is a Tris-HCl buffer containing NaCl with a pH value of 7.6-8.4, wherein the concentration of the Tris-HCl buffer is 10 mM-30 mM and the concentration of NaCl is 0.5 M-1.5 M;
[0130] Preferably, the pH value of the Tris-HCl buffer is 7.6, 7.8, 8.0, 8.2 or 8.4, the concentration of the Tris-HCl buffer is 10 mM, 15 mM, 20 mM, 25 mM or 30 mM; the concentration of NaCl is 0.5 M, 0.7 M, 0.8 M, 0.9 M, 1.0 M, 1.1 M, 1.2 M, 1.3 M, 1.4 M or 1.5 M;
[0131] Preferably, the elution flow rate of the heparin affinity chromatography is 30 cm / hour to 150 cm / hour, preferably 40 cm / hour to 120 cm / hour, and more preferably 60 cm / hour.
[0132] Hydrophobic chromatography
[0133] In some embodiments, the hydrophobic chromatography column filler is selected from agarose medium; preferably Butyl Bestarose HP;
[0134] Preferably, the eluent for the hydrophobic chromatography is a phosphate buffer containing NaCl with a pH value of 6.5-7.5, wherein the concentration of the phosphate buffer is 10 mM-30 mM and the concentration of NaCl is 0.5 M-2.5 M;
[0135] Preferably, the pH value of the phosphate buffer is 6.5, 6.6, 6.8, 7.0, 7.2 or 7.5, the concentration of the phosphate buffer is 10 mM, 15 mM, 20 mM, 25 mM or 30 mM; the concentration of NaCl is 0.5 M, 1.0 M, 1.5 M, 1.7 M, 1.9 M, 2.0 M, 2.1 M, 2.2 M, 2.4 M or 2.5 M;
[0136] Preferably, the elution flow rate of the hydrophobic chromatography is 30 cm / hour to 150 cm / hour, preferably 40 cm / hour to 120 cm / hour, more preferably 60 cm / hour.
[0137] Cation exchange chromatography followed by molecular sieve chromatography
[0138] In some embodiments, after the cation exchange chromatography, molecular sieve chromatography is further included;
[0139] Preferably, the filler of the molecular sieve chromatography is selected from gel filtration media, preferably Sephacryl, Superdex or Sephadex; more preferably Sephacryl S-200HR, Superdex75pg, Superdex200pg or SephadexG25.
[0140] Preferably, the eluent for the molecular sieve chromatography is a phosphate buffer having a pH value of 6.5-7.5, and a concentration of the phosphate buffer of 40 mM-80 mM; more preferably, the phosphate buffer has a pH value of 6.5, 6.6, 6.8, 7.0, 7.2 or 7.5, and a concentration of 40 mM, 50 mM, 60 mM, 70 mM or 80 mM;
[0141] Preferably, the elution flow rate of the molecular sieve chromatography is 5 cm / hour to 80 cm / hour, preferably 10 cm / hour to 35 cm / hour, more preferably 20 cm / hour.
[0142] Ultrafiltration
[0143] In some embodiments, after the anion exchange chromatography and before the cation exchange chromatography, an ultrafiltration step is further included;
[0144] Preferably, the specific steps of the ultrafiltration are: collecting the components corresponding to the target peak of the anion exchange chromatography and concentrating them 5-20 times with an ultrafiltration membrane, and then replacing the solution containing the components corresponding to the target peak with 10mM-30mM phosphate buffer, the pH value of the phosphate buffer is 6.5-7.5, and the molecular weight cutoff of the ultrafiltration membrane is 10kD-50kD;
[0145] Preferably, the concentration of the phosphate buffer is 10 mM, 15 mM, 20 mM, 25 mM or 30 mM, the pH value is 6.5, 6.6, 6.8, 7.0, 7.2 or 7.5, the ultrafiltration membrane molecular weight cut-off is 30 kD, and the concentration factor is 10 times.
[0146] Virus inactivation
[0147] In some embodiments, after obtaining the snake venom raw material solution and before performing anion chromatography purification, the step of performing virus inactivation treatment on the snake venom raw material solution is also included; preferably, the virus inactivation treatment is performed by S / D method.
[0148] In some preferred embodiments, the above extraction method can be used to extract or prepare the coagulation factor X activating enzyme of the present invention.
[0149] Glycosylation analysis methods
[0150] The present invention also provides a method for analyzing the glycosylation of coagulation factor X activating enzyme, the method comprising the following steps:
[0151] (1) Processing of factor X activating enzyme samples.
[0152] (2) Enzymatic hydrolysis of the treated samples.
[0153] (3) Analyzing the enzymatically hydrolyzed sample to obtain the sugar profile or glycosylation status of factor X activating enzyme.
[0154] In a specific embodiment, the step of treating the factor X activating enzyme sample in step (1) comprises urea solution treatment, DTT treatment, and iodoacetamide alkylation treatment. In some preferred embodiments, step (1) comprises: adding urea solution to the factor X activating enzyme sample, centrifuging; and sequentially treating with DTT (dithiothreitol) reduction and iodoacetamide alkylation.
[0155] In some embodiments, the concentration of urea is 4M-10M, preferably 8M;
[0156] In some embodiments, the concentration of DTT is 5mM-40mM, preferably 10mM.
[0157] In some embodiments, the DTT reduction condition is 45°C-65°C, preferably 56°C;
[0158] In some embodiments, the concentration of iodoacetamide is 20 mM-50 mM, preferably 30 mM.
[0159] In another specific embodiment, the enzymatic hydrolysis step in step (2) comprises the following steps: adding ammonium bicarbonate, then adding trypsin for treatment, and adding formic acid to terminate the reaction after the enzymatic hydrolysis reaction. In some preferred embodiments, step (2) comprises: adding ammonium bicarbonate solution, centrifuging, and then adding trypsin for enzymatic hydrolysis; after the enzymatic hydrolysis reaction is completed, adding formic acid solution to terminate the reaction, and ultrafiltration of the sample.
[0160] In some embodiments, the concentration of ammonium bicarbonate is 30 mM-80 mM, preferably 50 mM; preferably, the step of adding ammonium bicarbonate is repeated twice;
[0161] In some embodiments, the ratio of trypsin is 1:30-1:80, preferably 1:50. Preferably, the step of adding trypsin is repeated twice, and the reaction is carried out at 37°C.
[0162] In a specific embodiment, the analysis in step (3) is performed using liquid chromatography-mass spectrometry.
[0163] In some embodiments, the mobile phase of the liquid chromatography contains formic acid. In some preferred embodiments, the formic acid is added in a ratio of 1:5-1:30, preferably 1:20.
[0164] In some embodiments, the liquid chromatography column is a C18 column;
[0165] In some embodiments, the column temperature of the chromatographic column is 35°C-55°C, preferably 35°C-45°C, more preferably 40°C;
[0166] In some embodiments, the flow rate of the liquid chromatography is 0.1 ml / min-1 ml / min, preferably 0.1 ml / min-0.8 ml / min, more preferably 0.2 ml / min;
[0167] In some embodiments, the injection volume of the liquid chromatography is 2 μl-20 μl, preferably 4-15 μl, more preferably 6 μl-10 μl;
[0168] In some embodiments, the mobile phase of the liquid chromatography consists of a mobile phase A and a mobile phase B, wherein the mobile phase A is an aqueous solution of formic acid and trifluoroacetic acid, preferably an aqueous solution of (0.01%-0.2%) formic acid + (0.01%-0.2%) trifluoroacetic acid; more preferably an aqueous solution of (0.05%-0.1%) formic acid + (0.05%-0.1%) trifluoroacetic acid;
[0169] Mobile phase B is an acetonitrile solution of formic acid and trifluoroacetic acid, preferably an acetonitrile solution of (0.01%-0.2%) formic acid + (0.01%-0.2%) trifluoroacetic acid; more preferably an acetonitrile solution of (0.05%-0.1%) formic acid + (0.05%-0.1%) trifluoroacetic acid; preferably, the acetonitrile solution contains (80%-100%) acetonitrile and (0-20%) water, preferably 90% acetonitrile and 10% water.
[0170] In some preferred embodiments, the above-mentioned glycosylation analysis method can be used to analyze the factor X activating enzyme described in the present invention.
[0171] Terms and Definitions
[0172] To facilitate understanding of the content and embodiments of the present invention, the meanings of specific terms are as follows.
[0173] Glycosylation is the process of modifying proteins by attaching sugar chains. There are two common types of glycosylation: O-linked glycosylation and N-linked glycosylation. O-linked glycosylation involves the attachment of glycans to hydroxyl groups on proteins, such as serine (Ser) and / or threonine (Thr) residues. N-linked glycosylation involves the attachment of glycans to amide groups on proteins, such as asparagine (Asn) residues. Proteins are modified by glycosylation to form glycoproteins.
[0174] Glycan: refers to a polysaccharide, oligosaccharide or monosaccharide. A glycan can be a monomer or polymer of a sugar residue, and can also be linear or branched. Glycans can include natural sugar residues (e.g., glucose, N-acetylglucosamine, N-acetylneuraminic acid, galactose, mannose, fucose, hexose, arabinose, ribose, xylose, etc.) and / or modified sugars (e.g., 2'-fluororibose, 2'-deoxyribose, phosphomannose, 6'-sulfo N-acetylglucosamine, etc.). Glycans can contain homopolymers and heteropolymers of sugar residues. Glycans also encompass a glycan component of a conjugated sugar (e.g., a glycan component of a glycoprotein, glycolipid, or proteoglycan). Glycans also encompass free glycans, including glycans in which a conjugated sugar species has been cleaved or released by other means.
[0175] N-glycans: refers to N-linked polysaccharides or oligosaccharides. N-linked polysaccharides or oligosaccharides are polysaccharides or oligosaccharides that are linked to the amide group of an asparagine residue or an arginine residue in a protein, for example, through an N-acetylglucosamine residue. The basic structure, composition and types of N-linked polysaccharides are known in the art (see, for example, Drickamer K, Taylor ME (2006), Introduction to Glycobiology, 2 nd ed.; Editor: Ajit Varki et al., Essentials of Glycobiology, 4th edition, Cold Spring Harbor (NY): Cold Spring Harbor Laboratory Press; 2022, etc.). Specifically, the main sugars that make up N-glycans include: glucose, galactose, mannose, fucose, N-acetylgalactosamine (GalNAc), N-acetylglucosamine (GlcNAc), sialic acid (SA), etc. In some embodiments, the core structure of N-glycans is known in the art, that is, they all have a pentasaccharide core ( in, stands for acetylglucosamine GlcNAc, (Man stands for mannose, and can also be expressed as Man3GlcNAc2). N-glycans are extended from the basic pentasaccharide core. According to the branched components of the N-glycan, N-glycans can be classified into high mannose type, complex type or hybrid type. "High mannose type" N-glycans have 5 or more mannose residues. "Complex type" N-glycans usually have at least one GlcNAc attached to the 1,3 mannose arm of the pentasaccharide core. Complex type N-glycans may also have galactose or N-acetylgalactosamine residues, which may be modified with sialic acid or derivatives. Complex type N-glycans may also have multiple antennae on the pentasaccharide core and are often referred to as "multi-antennary glycans." "Hybrid type" N-glycans have at least one GlcNAc at the end of the 1'3 mannose arm of the pentasaccharide core and 0 or more mannose on the 1'6 mannose arm of the pentasaccharide core.
[0176] The naming rules of extended glycoforms are also well known to those skilled in the art. For example, they can be named using Oxford Notation (for example, see: David J. Harvey et al., Proposal for a standard system for drawing structural diagrams of N-and O-linked carbohydrates and related compounds, Proteomics 2009, 9, 3796–3801; Margaret Doherty et al., Plasma N-glycans in colorectal cancer risk, SCIENTIFIC REPORTS (2018) 8: 8655; Jerrard M Hayes et al., Identification of Fc Gamma Receptor Glycoforms That Produce Differential Binding Kinetics for Rituximab, Mol Cell Proteomics. 2017 Oct; 16(10): 1770-1788; https: / / www.ludger.com / product-catalogue / standards-controls / n-glycan-unlabelled, etc.). For example, take F2A3BG3S3 as an example, where F stands for fucose, and the number after F represents its number, i.e., F2 indicates that there are 2 fucoses; A stands for antenna (Antennary), that is, acetylglucosamine (GlcNAc) is added to the mannose (Man) of the pentasaccharide core, and the number after A represents its number of antennae, i.e., A3 indicates that its sugar chain is triantennary; B stands for bisected GlcNAc, that is, an acetylglucosamine (GlcNAc) is connected to the mannose (Man) in the middle of the pentasaccharide core; G stands for galactose, and the number after it represents its number, i.e., G3 indicates that there are 3 galactoses; S stands for sialic acid, and the number after it represents its number, i.e., S3 indicates that there are 3 sialic acids.
[0177] N-glycosylation: "N-glycosylation" and "N-linked glycosylation" are used interchangeably and refer to the process by which a sugar is attached to a linker group containing an asparagine residue or an arginine residue, or containing an N-linked glycosylation site or motif.
[0178] Isolated: An "isolated" biological component (e.g., a nucleic acid molecule, protein, virus, or cell) has been substantially separated or purified from the cells or tissues of the organism in which the component is naturally present, or from other biological components within the organism itself (e.g., other chromosomal and extrachromosomal DNA and RNA, proteins, and cells). Nucleic acid molecules and proteins that have been "isolated" include those purified by standard purification methods. The term also includes nucleic acid molecules and proteins prepared by recombinant expression in host cells, as well as chemically synthesized nucleic acid molecules and proteins.
[0179] Pharmaceutically acceptable carriers include any standard pharmaceutical carriers, such as phosphate buffered aqueous solutions, emulsions (such as oil / water or water / oil emulsions) and various types of wetting agents.
[0180] Treatment: A method of achieving a beneficial or desired outcome, including a clinical outcome. For the purposes of this invention, such beneficial or desired clinical outcomes include, but are not limited to, one or more of the following: relief of one or more symptoms caused by a disease, alleviation of the severity of the disease, stabilization of the disease (e.g., preventing or delaying worsening of the disease), prevention or delay of recurrence of the disease, delay or slowing of disease progression, improvement of the disease state, remission of the disease (partial or complete), reduction in the dose of one or more other drugs required to treat the disease, delay of disease progression, improvement or enhancement of quality of life, and / or prolongation of survival.
[0181] Therapeutically effective amount: The amount of a particular drug or therapeutic agent (e.g., Factor X activating enzyme) sufficient to achieve the desired effect in a subject or cell being treated with the agent. The effective amount of the agent depends on a variety of factors, including, but not limited to, the subject or cell being treated, and the manner in which the therapeutic composition is administered.
[0182] Signal peptide: This refers to the propeptide present as an N-terminal peptide on the precursor form of a protein. The function of the signal peptide is to facilitate translocation of the expressed polypeptide to the endoplasmic reticulum, where it is typically cleaved by a signal peptidase. The signal peptide can be heterologous or homologous to the organism producing the polypeptide.
[0183] The beneficial effects of the present invention are as follows:
[0184] 1. The present invention provides a novel factor X activating enzyme from Vipera rotundus, which has specific N-glycosylation modifications at four sites: Asn 28, Asn 69, Asn 163, and Asn 183 of the α chain, Asn 59 of the β chain, and Asn 24 of the γ chain. Compared to other RVV-X enzymes available in the prior art, this factor X activating enzyme has higher activity and will play an important role in the treatment of clinical bleeding and bleeding disorders.
[0185] 2. The present invention also provides a new method for extracting factor X activating enzyme from Vipera venom. Compared with existing methods, this method has a higher yield while ensuring high purity and high activity of the product, greatly reducing production costs, and is therefore more suitable for large-scale production.
[0186] Of course, it should be noted that the method of the embodiment of the present invention does not have to achieve all of the above advantages at the same time. BRIEF DESCRIPTION OF THE DRAWINGS
[0187] Figures 1A-1C show the alignment results of the translated cDNA sequence of the coagulation factor X activating enzyme α chain with sequence 2008 and sequence 1992 (Figure 1A), the alignment results of the translated cDNA sequence of the β chain with sequence 2008 (Figure 1B), and the alignment results of the translated cDNA sequence of the γ chain with sequence 2008 and sequence 1992 (Figure 1C), respectively.
[0188] Figures 2A-2C show the N-terminal sequence determination and alignment results of the factor X activating enzyme α chain (Figure 2A), β chain (Figure 2B), and γ chain (Figure 2C), respectively.
[0189] Figures 3A-3C show the prediction results of N-glycosylation sites for the α chain (Figure 3A), β chain (Figure 3B), and γ chain (Figure 3C) of coagulation factor X activating enzyme, respectively. The vertical lines represent the possibility of N-glycosylation, the corresponding horizontal axes represent possible N-glycosylation sites, and the horizontal lines represent the threshold value for the possibility of N-glycosylation. DETAILED DESCRIPTION
[0190] Example 1: Design of specific primers for amplification of factor X activating enzyme cDNA
[0191] Based on the known sequences of the three chains of factor X activating enzyme (i.e., α, β, and γ chains), the conserved homologous sequences for each chain were analyzed using the AlignX function in Vector NTI 11.5 software. Based on these results, specific primers were designed for cloning the cDNA coding sequences for the three chains and synthesized by Invitrogen. Primer sequences are shown in Table 1.
[0192] Table 1 Primers for amplification of factor X activating enzyme cDNA
[0193] Example 2: Amplification of the cDNA sequence of factor X activating enzyme
[0194] 1. Total RNA extraction and reverse transcription
[0195] The heads of Vipera rotundifolia were excised and quickly frozen on dry ice. The venom glands on both sides were isolated while still frozen, crushed, and added to a centrifuge tube containing 1 ml of Trizol (Takara, #9108-1). The tissue fragments were repeatedly pipetted until lysed. The tubes were allowed to stand at room temperature for 5 minutes. 200 μl of chloroform was then added and vortexed to mix. The tubes were allowed to stand at room temperature for 5 minutes and then centrifuged at 12,000 rpm for 10 minutes. The supernatant was carefully transferred to another centrifuge tube, and an equal volume of isopropanol was added. The tubes were mixed and allowed to stand at room temperature for 10 minutes and then centrifuged at 12,000 rpm for 10 minutes. The supernatant was discarded, and 1 ml of 75% ethanol was added to the tubes. The tubes were centrifuged at 12,000 rpm for 10 minutes. The supernatant was removed as much as possible, air-dried for 5 minutes, and RNA was dissolved in 20 μl of DEPC-treated water and stored frozen.
[0196] Reverse transcription was performed on the extracted total RNA using a reverse transcription kit (Fermentas, #K1622). The reaction mixture was prepared according to the manufacturer's instructions. 4 μl of total RNA was added to 7 μl of DEPC water and 1 μl of Oligo T. Mix thoroughly, incubate at 65°C for 5 minutes, and immediately place on ice. Add 4 μl of 5× buffer, 1 μl of RNase Inhibitor, 1 μl of MMLV, and 2 μl of dNTPs to the reaction mixture. Mix thoroughly, briefly centrifuge, incubate at 42°C for 60 minutes, and then treat at 75°C for 5 minutes. The resulting cDNA product can be directly used for PCR amplification.
[0197] 2. Specific amplification of reverse transcribed cDNA
[0198] Using the cDNA obtained by reverse transcription as a template, PCR amplification was performed using the three pairs of primers synthesized in Example 1. The reaction system is shown in Table 2:
[0199] Table 2 Coagulation factor X activating enzyme cDNA amplification system
[0200] PCR reaction conditions are:
[0201] The PCR product was analyzed by agarose gel electrophoresis, and a single, clear amplified band was obtained, and the position of the band was consistent with the expected size. The band was cut out and placed in an EP tube and stored at 4°C.
[0202] 3. Gel recovery, ligation of T vector and sequencing
[0203] The excised target bands were recovered from the gel using a gel recovery kit (TIANGEN, #DP209-02). The recovered product was ligated with a T vector and transformed into competent E. coli cells. Five single clones were plated and propagated in LB liquid medium. Plasmids were extracted and sent to Takara for nucleic acid sequencing to obtain cDNA sequence information for the α, β, and γ chains of coagulation factor X activating enzyme.
[0204] Example 3: Determination of the amino acid sequence of factor X activating enzyme
[0205] 1. α chain analysis
[0206] Based on the α chain cDNA sequence information obtained in Example 2, open reading frame (ORF) analysis was performed using Vector NTI. According to the analysis results, the translated protein sequence is as follows (SEQ ID NO: 7), wherein amino acids 1-20 are the signal peptide sequence (in bold), amino acids 21-188 are the propeptide sequence (indicated by underline), and amino acids 189-619 are the mature peptide sequence.
[0207] The amino acid sequence of the α chain after removing the signal peptide and propeptide is as follows (SEQ ID NO: 8, 431 amino acids):
[0208] 2. β-chain analysis
[0209] Based on the cDNA sequence information of the β chain obtained in Example 2, open reading frame (ORF) analysis was performed using Vector NTI. According to the analysis results, the resulting protein sequence is as follows (SEQ ID NO: 9), wherein positions 1-23 are the signal peptide sequence (indicated in bold); positions 24-158 are the mature peptide sequence.
[0210] The amino acid sequence of the β chain without the signal peptide is as follows (SEQ ID NO: 10, 135 amino acids):
[0211] 3. γ chain analysis
[0212] Based on the cDNA sequence information of the γ chain obtained in Example 2, open reading frame (ORF) analysis was performed using Vector NTI. According to the analysis results, the translated protein sequence is as follows (SEQ ID NO: 11), wherein positions 1-23 are the signal peptide sequence (in bold); positions 24-146 are the mature peptide sequence:
[0213] The amino acid sequence of the γ chain without the signal peptide is as follows (SEQ ID NO: 12, 123 amino acids):
[0214] Example 4: Verification of the amino acid sequence structure of factor X activating enzyme
[0215] 1. Amino acid sequence alignment
[0216] The amino acid sequences of the three mature peptides obtained in Example 3 (i.e., α chain, β chain, and γ chain, indicated by “cDNA translation”) were compared with the amino acid sequences (indicated by “sequence 2008”) obtained by translating the cDNA sequence determined in 2008 by Chen HS et al. (Chen HS et al., New insights into the functions and N-glycan structures of factor X activator from Russell's viper venom. FEBS J. 2008 Aug; 275(15): 3944-58) (Gene Bank accession numbers DQ137799, AY734997, and AY734998, respectively), and the amino acid sequences (indicated by “sequence 2008”) obtained by Takeya H. et al. (Takeya H et al., Coagulation factor X activating enzyme from Russell's viper venom (RVV-X). A novel metalloproteinase with disintegrin (platelet aggregation inhibitor)-like and C-type lectin-like domains. J Biol Chem. 1992 Jul) respectively. 15; 267(20): 14109-17.) were compared with the amino acid sequences determined by the Edman degradation method in 1992 (only the α chain and γ chain sequences were detected, represented by "Sequence 1992"). The comparison results are shown in Figures 1A-1C, where bold letters indicate different amino acid residues at that position, a horizontal line "-" indicates that the amino acid residues at that position are the same, and a dot "." indicates that the amino acid residue at that position was not detected.
[0217] The alignment of the translated α chain cDNA sequence with sequence 2008 and sequence 1992 is shown in Figure 1A . The alignment of the translated β chain cDNA sequence with sequence 2008 is shown in Figure 1B . The alignment of the translated γ chain cDNA sequence with sequence 2008 and sequence 1992 is shown in Figure 1C .
[0218] 2. N-terminal sequence analysis and confirmation
[0219] To confirm the presence of the mature peptide translated from the cDNA in Vipera rotundus, factor X activating enzyme (FX-activating enzyme) was extracted, purified, and obtained from the venom of the Vipera rotundus. The N-terminal sequences of the FX-activating enzyme α, β, and γ chains were determined by tandem mass spectrometry and Edamn degradation, respectively, commissioned by the Beijing Proteome Research Center and the School of Life Sciences of Peking University.
[0220] The amino acid sequences of the mature peptides translated from the α-chain, β-chain, and γ-chain cDNA sequences (indicated by "cDNA translation"), the results of sequence identification by mass spectrometry (indicated by "mass spectrometry"), and the results of Edman degradation determination (indicated by "Edman method") were compared with "Sequence 1992". The results are shown in Figures 2A-2C.
[0221] The results of the α-chain N-terminal sequence determination and alignment are shown in Figure 2A . Mass spectrometry identified that the 35 N-terminal amino acids of the α-chain were consistent with the amino acid sequence at the same position in the cDNA translation sequence.
[0222] Edman degradation analysis of the amino acid sequence at the N-terminus of the α-chain showed that the detection result at each position was not a single amino acid, and a complete sequence could not be obtained. This is consistent with the phenomenon of heterogeneity at the N-terminus found by Kisiel W et al. in 1976 when they used Edman degradation to detect the N-terminal amino acid of the RVV-X α-chain (Kisiel W et al., Factor X activating enzyme from Russell's viper venom: isolation and characterization. Biochemistry. 1976 Nov 2; 15(22): 4901-6.).
[0223] The results of β-chain N-terminal sequence determination and alignment are shown in Figure 2B . The N-terminal 63 amino acids identified by mass spectrometry were consistent with the amino acid sequence at the same position in the cDNA translation sequence, and the N-terminal 30 amino acid sequence determined by Edman degradation was consistent with the amino acid sequence at the same position in the cDNA translation sequence.
[0224] The results of the γ-chain N-terminal sequence determination and alignment are shown in Figure 2C, where "X" indicates unidentified amino acids. Edman degradation identified a total of 30 N-terminal amino acids. With the exception of amino acid position 24, all other amino acids were consistent with the cDNA translation sequence and Sequence 1992. Mass spectrometry did not capture the first 17 amino acids of the γ-chain N-terminus. The sequence of amino acids 18 to 47 was consistent with the cDNA translation sequence and Sequence 1992 at the same positions.
[0225] The results of subsequent glycosylation site confirmation tests showed that the amino acid at position 24 is N (Asn, asparagine), and N-glycosylation modification exists. It is speculated that the reason why the amino acid residue at position 24 was not captured may be that the glycosylation modification affected the determination of this amino acid by the Edman degradation method.
[0226] In summary, the N-terminal amino acid sequences of the three chains of the coagulation factor X activating enzyme described herein are:
[0227] α chain N-terminal 35 amino acid residues (SEQ ID NO: 13):
[0228] β-chain N-terminal 63 amino acid residues (SEQ ID NO: 14):
[0229] N-terminal 47 amino acid residues of the γ chain (SEQ ID NO: 15):
[0230] The results of N-terminal amino acid sequencing of factor X activating enzyme were consistent with the N-terminal sequence of the mature peptide obtained by cDNA translation, indicating that the mature peptide obtained by cDNA translation exists in the venom of Vipera rotundus.
[0231] Through the above structural confirmation and comparison with sequences in GeneBank and EMBL libraries, it was confirmed that the present invention obtained a new coagulation factor X activating enzyme from Vipera rotundus.
[0232] Example 5: Confirmation of glycosylation sites of factor X activating enzyme
[0233] The NeNGlycl.0Server neural network software (URL: http: / / www.cbs.dtu.dk / services / NetNGlyc / ) was used to analyze the cDNA translation sequences of the α, β, and γ chains of coagulation factor X activating enzyme to predict the N-glycosylation sites that may be glycosylated in these three chains.
[0234] The analysis results for the α, β, and γ chains are shown in Figures 3A-3C. The vertical lines in the figures correspond to sites with sequence features consistent with N-glycosylation, namely, Asn-X-Thr / Ser. The vertical lines indicate the likelihood of N-glycosylation. The horizontal lines indicate the threshold for N-glycosylation likelihood, which is 0.5. A score ≥ 0.5 indicates that the site is a predicted glycosylation site.
[0235] The prediction results of α-chain N-glycosylation sites are shown in Figure 3A. The possible N-glycosylation sites from the N-terminus are 28NSTA, 69NVTS, and 183NCSI, with scores of 0.7407, 0.7516, and 0.6519, respectively. The score of 163NDSS is 0.4979, close to 0.5, and it is also used as a site where N-glycosylation modification may occur for subsequent experimental analysis.
[0236] The prediction results of the β-chain N-glycosylation site are shown in Figure 3B . The possible N-glycosylation site is 59NITE, with a score of 0.7391.
[0237] The prediction results of the γ-chain N-glycosylation site are shown in Figure 3C . The possible N-glycosylation site is 24NWTD, with a score of 0.6089.
[0238] Subsequently, the Beijing Proteome Research Center was commissioned to use mass spectrometry to analyze and confirm the six N-glycosylation sites of the three chains. The results showed that N-glycosylation modification occurred at all six sites, which was consistent with the predicted results.
[0239] Example 6: New Extraction Method for Factor X Activating Enzyme
[0240] 1. Extraction of Factor X Activating Enzyme
[0241] This example explores the process of extracting factor X activating enzyme from Vipera venom.
[0242] About 10 ml of the Vipera venom was taken and diluted with 20 mM Tris-HCl solution (pH 8.5) to a protein concentration of about 20-30 mg / ml. The mixture was centrifuged at 12,000×g for 20 minutes at 4° C., and the supernatant was collected.
[0243] Snake venom raw material was inactivated using the S / D method. The specific steps were as follows: After filtering the collected supernatant through a 0.45 μm filter, Tween-80 and tributyl phosphate were added sequentially to a final Tween-80 concentration of 1% and tributyl phosphate concentration of 0.3%. After thorough mixing, the mixture was incubated in a water bath at 25°C ± 2°C for 2 hours to inactivate the virus. Factor X activating enzyme was extracted from the snake venom obtained by virus inactivation according to the steps listed in Table 3:
[0244] Table 3 Overview of extraction methods for factor X activating enzyme
[0245] The specific steps are as follows:
[0246] 1.1 Anion exchange chromatography-cation exchange chromatography
[0247] (1) Anion exchange chromatography
[0248] The Q Sepharose HP chromatography column was equilibrated with 20 mM Tris-HCl (pH 8.5) buffer for 3 column volumes before use.
[0249] Virus-inactivated snake venom was loaded at a flow rate of 90 cm / h. After loading, the mixture was washed to baseline with 20 mM Tris-HCl (pH 8.5) at a flow rate of 90 cm / h. The mixture was then washed again with 20 mM Tris-HCl-0.2 M NaCl (pH 8.5) at a flow rate of 90 cm / h.
[0250] After washing, elute with 20%-100% 20 mM Tris-HCl-0.4 M NaCl (pH 8.5) for 10 column volumes at a flow rate of 90 cm / hour. When the conductivity reaches 10 ms / cm, the target peak begins to appear, and fractions corresponding to the target peak are collected. Collection is stopped when the target peak descends to the baseline.
[0251] (2) Ultrafiltration concentration
[0252] The fraction corresponding to the target peak collected by anion chromatography was concentrated approximately 10-fold using a 30 kD ultrafiltration membrane, and then the concentrate was replaced with an equal volume of 20 mM phosphate buffer (pH 6.8).
[0253] (3) Cation exchange chromatography
[0254] The Capto SP ImpRes column was equilibrated with 10 mM phosphate buffer (pH 6.8) for 3 column volumes, and the ultrafiltration fraction was loaded at a flow rate of 60 cm / h. After loading, the column was reequilibrated with 10 mM phosphate buffer until the baseline was stable at a flow rate of 60 cm / h.
[0255] After equilibration, linear elution was performed with 0-100% 10 mM phosphoric acid + 0.4 M NaCl (pH 6.8) solution for 5 column volumes at a flow rate of 60 cm / h. The target peak was collected when the conductivity increased to 10±1 ms / cm and a clear inflection point appeared in the UV. Collection was stopped when the conductivity increased to 18±1 ms / cm and the UV decreased until the next peak rose.
[0256] 1.2 Cation exchange chromatography-anion exchange chromatography
[0257] (1) Cation exchange chromatography
[0258] The CM Beads 6FF chromatography column was equilibrated with 10 mM (pH 6.8) phosphate buffer for 3 column volumes, and then the virus-inactivated fraction was loaded at a flow rate of 60 cm / h. After loading, the column was re-equilibrated with 10 mM phosphate buffer until the baseline was stable at a flow rate of 60 cm / h.
[0259] After equilibration, 0-100% 10 mM phosphoric acid + 0.4 M NaCl (pH 6.8) solution was linearly eluted over 5 column volumes at a flow rate of 60 cm / h to collect the components corresponding to the target peak.
[0260] (2) Ultrafiltration
[0261] The fraction corresponding to the target peak collected by cation chromatography was concentrated approximately 10-fold using a 30 kD ultrafiltration membrane, and then the concentrate was replaced with an equal volume of 20 mM Tris-HCl buffer (pH 8.5).
[0262] (3) Anion exchange chromatography
[0263] Before use, equilibrate the NenoGel 50Q column with 20 mM Tris-HCl (pH 8.5) buffer for 3 column volumes. Load the ultrafiltered sample at a flow rate of 90 cm / hour. After loading, reequilibrate with 20 mM Tris-HCl (pH 8.5) to a stable baseline at a flow rate of 90 cm / hour. Wash with 20 mM Tris-HCl-0.2 M NaCl (pH 8.5) at a flow rate of 90 cm / hour.
[0264] After washing, elute with 20%-100% 20 mM Tris-HCl-0.4 M NaCl (pH 8.5) for 10 column volumes at a flow rate of 90 cm / hour. When the conductivity reaches 10 ms / cm, the target peak begins to appear, and fractions corresponding to the target peak are collected. Collection is stopped when the target peak descends to the baseline.
[0265] 1.3 Molecular sieve chromatography-anion exchange chromatography-cation exchange chromatography
[0266] The virus-inactivated snake venom was first subjected to molecular sieve chromatography using the following conditions: a G25 column (≥2 CV) was fully equilibrated with 0.02 mol / L Tris-HCl (pH 8.5) at a flow rate of 60 cm / hour. The virus-inactivated snake venom was then loaded at a volume of 20%-30% of the column volume, followed by a subsequent rinse with the equilibration solution. The target fluid was collected when the UV absorbance (UV) value reached approximately 1 mAU and ceased collection when the UV value dropped to 250 ± 50 mAU.
[0267] The collected fractions were subjected to anion exchange chromatography, ultrafiltration, and cation exchange chromatography in sequence according to steps (1) to (3) of method 1.1 to collect the fractions corresponding to the target peak.
[0268] 1.4 Molecular sieve chromatography-cation exchange chromatography-cation exchange chromatography
[0269] (1) Molecular sieve chromatography
[0270] The virus-inactivated snake venom was subjected to molecular sieve chromatography according to method 1.3.
[0271] (2) Cation exchange chromatography
[0272] The Capto SP ImpRes column was equilibrated with 10 mM (pH 6.8) phosphate buffer for 3 column volumes, and the fractions obtained by molecular sieve chromatography were then loaded at a flow rate of 60 cm / h. After loading, the column was reequilibrated with 10 mM phosphate buffer until the baseline was stable at a flow rate of 60 cm / h.
[0273] After equilibration, 0-100% 10 mM phosphoric acid + 0.4 M NaCl (pH 6.8) solution was linearly eluted over 5 column volumes at a flow rate of 60 cm / h to collect the components corresponding to the target peak.
[0274] (3) Ultrafiltration
[0275] The fraction corresponding to the target peak collected by cation chromatography was concentrated approximately 10-fold using a 30 kD ultrafiltration membrane, and then the concentrate was replaced with an equal volume of 10 mM phosphate buffer (pH 6.8).
[0276] (4) Cation exchange chromatography
[0277] The ultrafiltration fractions were subjected to cation exchange chromatography using CM Beads 6FF: the CM Beads 6FF column was equilibrated with 10 mM (pH 6.8) phosphate buffer for 3 column volumes, and then the ultrafiltration fractions were loaded at a flow rate of 60 cm / h. After loading, the column was reequilibrated with 10 mM phosphate buffer until the baseline was stable at a flow rate of 60 cm / h.
[0278] After equilibration, 0-100% 10 mM phosphoric acid + 0.4 M NaCl pH (6.8) solution was linearly eluted over 5 column volumes at a flow rate of 60 cm / h, and the components corresponding to the target peak were collected.
[0279] 1.5 Molecular sieve chromatography-anion exchange chromatography-cation exchange chromatography
[0280] The virus-inactivated snake venom was purified according to method 1.3, except that a NenoGel 50Q column was used as the anion exchange chromatography column.
[0281] 1.6 Anion exchange chromatography-cation exchange chromatography-molecular sieve chromatography
[0282] Referring to the steps of method 1.1, the virus-inactivated snake venom was subjected to anion exchange chromatography, ultrafiltration, and cation exchange chromatography in sequence to collect the corresponding components.
[0283] The collected fractions were then subjected to molecular sieve chromatography again using the following conditions: A Sephacry1 S-200HR column was equilibrated with 50 mM (pH 6.8) phosphate buffer for three column volumes before loading. The loading volume was controlled to be 5% of the molecular sieve column volume. The chromatography flow rate was 20 cm / h, and fractions corresponding to the target peak were collected.
[0284] 1.7 Molecular sieve chromatography-anion exchange chromatography-cation exchange chromatography-molecular sieve chromatography
[0285] Referring to the steps of method 1.3, molecular sieve chromatography, anion exchange chromatography, ultrafiltration and cation exchange chromatography were performed in sequence to collect the corresponding fractions.
[0286] The collected fractions were then subjected to molecular sieve chromatography using the following conditions: a Sephacry1 S-200HR column was equilibrated with 50 mM (pH 6.8) phosphate buffer for three column volumes prior to loading. The loading volume was controlled to be 5% of the molecular sieve column volume. The chromatography flow rate was 20 cm / h, and fractions corresponding to the target peak were collected.
[0287] 1.8 Molecular sieve chromatography-anion exchange chromatography-cation exchange chromatography-molecular sieve chromatography
[0288] The virus-inactivated snake venom was purified according to the steps of method 1.7, except that a NenoGel 50Q column was used as the anion exchange chromatography column.
[0289] 1.9 Molecular sieve chromatography-anion exchange chromatography-cation exchange chromatography-molecular sieve chromatography
[0290] The virus-inactivated snake venom was purified according to the steps of method 1.7, except that a NenoGel 50SP column was used as the cation exchange chromatography column.
[0291] 1.10 Molecular sieve chromatography-anion exchange chromatography-cation exchange chromatography-molecular sieve chromatography
[0292] The virus-inactivated snake venom was purified according to the steps of method 1.7, except that a CM Beads 6FF column was used as the cation exchange chromatography column.
[0293] 1.11 Molecular sieve chromatography-anion exchange chromatography-cation exchange chromatography-hydrophobic chromatography
[0294] Referring to the steps of method 1.3, molecular sieve chromatography, anion exchange chromatography, ultrafiltration, and cation exchange chromatography were performed in sequence to collect the corresponding fractions, and then the collected fractions were subjected to hydrophobic chromatography. The specific conditions were as follows: the conductivity of the sample was adjusted to 140±5ms / cm; the Butyl Bestarose HP chromatography column was fully equilibrated with 20mM phosphoric acid + 2M NaCl (pH 7.0) buffer for 3 column volumes before use and the sample was loaded; the flow rate was 60cm / h; after the loading was completed, the chromatography column was re-equilibrated with 20Mm phosphoric acid + 2M NaCl pH7.0 solution until the baseline was stable, and the flow rate was 60cm / h.
[0295] After equilibration, the column was linearly eluted with 0-100% 20 mM (pH 6.8) phosphate buffer for 5 column volumes at a flow rate of 60 cm / h, and the fractions corresponding to the target peak were collected.
[0296] 1.12 Molecular sieve chromatography-anion exchange chromatography-cation exchange chromatography-hydrophobic chromatography
[0297] Molecular sieve chromatography, anion exchange chromatography, ultrafiltration, cation exchange chromatography, and hydrophobic chromatography were performed in sequence according to the steps of method 1.11, and the corresponding fractions were collected. The only difference was that the cation exchange chromatography column used was a NenoGel 50SP column.
[0298] 1.13 Molecular sieve chromatography-anion exchange chromatography-cation exchange chromatography-heparin affinity chromatography
[0299] Molecular sieve chromatography, anion exchange chromatography, ultrafiltration, and cation exchange chromatography were performed sequentially according to the procedures in Method 1.3. The corresponding fractions were collected and then subjected to heparin affinity chromatography. The specific conditions were as follows: the Capto heaparin column was fully equilibrated with 20 mM Tris-HCl (pH 8.0) buffer for 3 column volumes before loading the sample; the flow rate was 60 cm / h. After loading, the column was reequilibrated with 20 mM Tris-HCl (pH 8.0) buffer until the baseline was stable; the flow rate was 60 cm / h.
[0300] After equilibration, 0-100% 20 mM Tris-HCl + 1 M NaCl (pH 8.0) solution was linearly eluted for 5 column volumes at a flow rate of 60 cm / h to collect the components corresponding to the target peak.
[0301] 1.14 Heparin affinity chromatography-anion exchange chromatography-cation exchange chromatography
[0302] (1) The virus-inactivated snake venom was subjected to heparin affinity chromatography under the following conditions:
[0303] The Capto heaparin column was fully equilibrated with 20 mM Tris-HCl (pH 8.0) buffer for three column volumes before loading at a flow rate of 60 cm / h. After loading, the column was reequilibrated with 20 mM Tris-HCl (pH 8.0) buffer until the baseline was stable at a flow rate of 60 cm / h. After equilibration, a linear elution with 0-100% 20 mM Tris-HCl + 1 M NaCl (pH 8.0) was performed over five column volumes at a flow rate of 60 cm / h to collect the fractions corresponding to the target peak.
[0304] (2) Ultrafiltration
[0305] The fraction corresponding to the target peak collected by heparin affinity chromatography was concentrated approximately 10-fold using a 30 kD ultrafiltration membrane, and then the concentrate was replaced with an equal volume of 20 mM Tris-HCl buffer (pH 8.5).
[0306] Subsequently, the fractions obtained through heparin affinity chromatography were subjected to anion exchange chromatography, ultrafiltration, and cation exchange chromatography in sequence according to method 1.1, and the corresponding fractions were collected.
[0307] 1.15 Heparin affinity chromatography-anion exchange chromatography-cation exchange chromatography-molecular sieve
[0308] Heparin affinity chromatography, anion exchange chromatography, ultrafiltration, and cation exchange chromatography were performed sequentially according to the procedures of method 1.14. The corresponding fractions were collected and then subjected to molecular sieve chromatography. The specific conditions were as follows: A Sephacry1 S-200HR column was equilibrated with 50 mM (pH 6.8) phosphate buffer for 3 column volumes before loading. The loading volume was controlled to be 5% of the molecular sieve column volume. The chromatography flow rate was 20 cm / h, and the fractions corresponding to the target peak were collected.
[0309] 1.16 Hydrophobic chromatography-anion exchange chromatography-cation exchange chromatography
[0310] (1) The virus-inactivated snake venom was subjected to hydrophobic chromatography under the following conditions: the conductivity of the sample was adjusted to 80 ± 5 ms / cm; the Butyl Bestarose HP column was fully equilibrated with 20 mM phosphoric acid + 1 M NaCl pH 7.0 buffer for 3 column volumes before loading; the flow rate was 60 cm / h; after loading, the column was re-equilibrated with 20 mM phosphoric acid + 1 M NaCl pH 7.0 solution until the baseline was stable; the flow rate was 60 cm / h. The flow-through was collected as the target peak.
[0311] (2) Ultrafiltration concentration
[0312] The fraction corresponding to the target peak collected by hydrophobic chromatography was concentrated approximately 10-fold using a 30 kD ultrafiltration membrane, and then the concentrate was replaced with an equal volume of 20 mM Tris-HCl buffer (pH 8.5).
[0313] The fractions obtained by ultrafiltration were subjected to anion exchange chromatography, ultrafiltration, and cation exchange chromatography in sequence according to the method in 1.1, and the fractions corresponding to the target peaks were collected.
[0314] 1.17 Hydrophobic chromatography-anion exchange chromatography-cation exchange chromatography-molecular sieve
[0315] Hydrophobic chromatography, ultrafiltration, anion exchange chromatography, ultrafiltration, and cation exchange chromatography were performed in sequence according to the procedure of method 1.16. The corresponding fractions were collected and then subjected to molecular sieve chromatography. The specific conditions were as follows: Before use, the Sephacry1 S-200HR chromatography column was fully equilibrated with 50 mM (pH 6.8) phosphate buffer for 3 column volumes before loading. The loading volume was controlled to be 5% of the molecular sieve column volume. The chromatography flow rate was 20 cm / h, and the fractions corresponding to the target peak were collected.
[0316] 2. Detection methods and results
[0317] (1) Detection method
[0318] The coagulation factor X activating enzyme obtained by method 1.1-1.17 was detected according to the following method:
[0319] Protein yield testing: The total protein concentration of snake venom at the time of feeding was determined using the BCA assay. The total protein mass at the time of feeding was calculated based on the volume of the feed solution. The protein concentration of the purified factor X activator was determined using the Lowry method (Method 2, Protein Content Assay, Part 0731, General Chapter 0731, Part III, of the 2015 edition of the Chinese Pharmacopoeia). The volume was measured to determine the total mass of the final purified protein. The product yield was calculated by comparing the total protein mass at the time of feeding.
[0320] Protein purity test: Purity test was performed using size exclusion high performance liquid chromatography (SEC-HPLC).
[0321] (2) Test results
[0322] The results of the factor X activating enzyme assays obtained using methods 1.1-1.17 are shown in Table 4.
[0323] Table 4 Detection results of coagulation factor X kinase
[0324] According to the above results, we can conclude that:
[0325] (1) For the extraction of factor X activating enzyme from Vipera rotundus, if the extraction is performed sequentially using one anion exchange chromatography step and one cation exchange chromatography step (method 1.1), the purity of the final product can reach 97.75% as determined by SEC-HPLC, which is comparable to other methods in the prior art; and the product yield is as high as 4.96%, which is significantly higher than other methods in the prior art (for example, Examples 5.2-5.3 of CN109943554A, after anion exchange chromatography and CHT purification, the yield is 3.05%-3.49%).
[0326] However, if the order of anion chromatography and cation chromatography was reversed (method 1.2), or two cation exchange chromatography steps were performed (method 1.4), the purity of the final product was only 41.08% and 68.29% as determined by SEC-HPLC, which was much lower than that of method 1.1.
[0327] These results demonstrate that the sequential combination of anion exchange chromatography and cation exchange chromatography is essential for extracting factor X activator from Vipera rotundus to obtain high-purity and high-yield factor X activator. Furthermore, only one anion exchange chromatography step and one cation exchange chromatography step are required, eliminating the need for additional purification steps to obtain a high-purity product that meets the requirements.
[0328] (2) Based on the sequential combination of anion exchange chromatography and cation exchange chromatography, a purification step such as molecular sieve chromatography, hydrophobic chromatography, or heparin affinity chromatography is used before the anion exchange chromatography (Methods 1.3, 1.5, 1.14, and 1.16). The final product can maintain high purity (the purity reaches more than 98% as detected by SEC-HPLC), and the product yield still reaches 3.52%-5.92%, which is better than the methods in the prior art (for example, Examples 6-9 of CN109943554A, after purification by anion exchange chromatography, CHT, and molecular sieve chromatography, the yield is 2.69-2.82%).
[0329] (3) Based on the sequential combination of anion exchange chromatography and cation exchange chromatography, a molecular sieve chromatography step is performed after the cation exchange chromatography (Methods 1.6-1.10, 1.15, and 1.17), which can increase the purity of the final product to 100%. Although the yield is reduced (3.13%-4.01%), this may be due to the excessive number of purification steps. However, with the same number of purification steps (Method 1.6) and even with the additional chromatography step (Methods 1.7-1.10, 1.15, and 1.17), the yield of the method of the present invention is still better than that of the prior art (for example, Examples 6-9 of CN109943554A, after purification by anion exchange chromatography, CHT, and molecular sieve chromatography, the yield is 2.69-2.81%).
[0330] However, when cation exchange chromatography was followed by hydrophobic chromatography or heparin affinity chromatography (1.11, 1.12, and 1.13), despite the additional purification step, the purity of the final product as determined by SEC-HPLC actually decreased (11.76%, 13.33%, and 94.76%). Simultaneously, the product yield also decreased to varying degrees (1.53% to 2.20%).
[0331] The above results indicate that, based on the sequential combination of one anion exchange chromatography and one cation exchange chromatography, a molecular sieve chromatography step can be added to further improve the purity, or no other purification steps can be performed.
[0332] In summary, the method of the present invention can extract coagulation factor X activating enzyme from the venom of Vipera rotundus, improve the product yield while ensuring the high purity of the final product, greatly reduce production costs, and is more suitable for large-scale production.
[0333] Example 7: Structural Characterization and Activity Assay of Vipera Viper Factor X Activase
[0334] The factor X activating enzyme samples purified by methods 1.1, 1.6 and 1.7 in Example 6 were respectively selected for further structural characterization and activity determination.
[0335] 1. Further confirm the amino acid sequence of factor X activating enzyme
[0336] The coagulation factor X activating enzyme was further identified by mass spectrometry. The results showed that the amino acid sequence of the coagulation factor X activating enzyme was completely consistent with that of the coagulation factor X activating enzyme determined in Example 3 (the specific data are not shown).
[0337] 2. Analysis and identification of glycosylation modifications at various N-glycosylation sites in factor X activating enzyme
[0338] Factor X activating enzyme was centrifuged at 13,000 rpm for 10 min. 400 μl of 8 M urea solution was added and the mixture was centrifuged at 13,000 rpm for 10 min. DTT solution was added to a final concentration of 10 mM and the mixture was reacted at 56°C for 1 h. Iodoacetamide (IAM) solution was added to a final concentration of 30 mM and the mixture was reacted in the dark at room temperature for 40 min. DTT solution was again added to a final concentration of 10 mM to neutralize excess IAM solution. 350 μl of 50 mM ammonium bicarbonate solution was added and the mixture was centrifuged at 13,000 rpm for 10 min. The lower layer was discarded and this step was repeated twice. Trypsin was added at a 1:50 ratio and reacted at 37°C for 2 h. Trypsin was then added again according to the above enzyme dosage and reacted at 37°C overnight. Formic acid solution was added at a 1:20 ratio to terminate the enzymatic digestion reaction. The sample was transferred to an EP tube, the ultrafiltration tube was washed twice, and the volume was fixed.
[0339] Accurately measure 40 μl of sample solution and inject it into liquid chromatography-mass spectrometer for analysis:
[0340] Chromatographic conditions:
[0341] The chromatographic column is ACQUITY CSHTM C18, 1.7 μm, 2.1*150 mm column; column temperature: 40°C, sample temperature: 7°C, flow rate: 0.2 ml / min, detection wavelength: 214 nm; injection volume: 10 μl, mobile phase A: 0.05% FA + 0.05% TFA / water, mobile phase B: 0.05% FA + 0.05% TFA / (90% acetonitrile + 10% water).
[0342] The gradient elution program is shown in Table 5:
[0343] Table 5 Elution program
[0344] Mass spectrometer detection:
[0345] Analysis time: 120 min, detection mode: positive ion, parent ion scan range: 300-2000 m / z, primary mass spectrometry resolution: 70,000 at m / z 200, secondary mass spectrometry resolution: 17,500 at m / z 200.
[0346] The identification results showed that all three factor X activating enzyme samples had high glycosylation levels at the six glycosylation sites of the three peptide chains, with each site displaying multiple N-glycan modifications. Notably, although the γ and β chains have similar sequence lengths and each has only one N-glycosylation site, the glycosylation at Asn24 in the former is generally more complex than that at Asn59 in the latter, with a greater variety of N-glycan types (specific data not shown).
[0347] The results of the analysis of the major N-glycoforms and their relative contents at four sites (Asn 28, Asn 69, Asn 163, and Asn 183) of the α chain are shown in Table 6 .
[0348] Table 6 Main glycoforms and relative contents at each site of the α chain of the test sample
[0349] The results of the analysis of the main N-glycoforms and their relative contents at Asn 59 of the β chain are shown in Table 7:
[0350] Table 7 Main glycoforms and relative contents at each site of the β chain of the test sample
[0351] The results of the analysis of the main N-glycoforms and their relative contents at the γ-chain Asn 24 site are shown in Table 8:
[0352] Table 8 Main glycoforms and relative contents at each site of the γ chain of the test sample
[0353] 3. Detection of factor X activating enzyme activity
[0354] The three samples of factor X activating enzyme were assayed for enzyme activity according to the method described in "Determination of the Activity of Factor X Activator from Vipera Vipera by a Biochromatic Continuous Rate Method" (Chinese Journal of Medicine, 2007, Vol. 16, No. 18). The assay results showed that the specific activities of factor X activating enzymes obtained by methods 1.1, 1.6, and 1.7 of the present invention were 37,589.2 U / mg, 38,556.5 U / mg, and 37,992.8 U / mg, respectively.
Claims
1. A coagulation factor X activating enzyme, characterized in that The coagulation factor X activating enzyme includes three polypeptide chains: α, β, and γ. The amino acid sequence of the α chain is shown in SEQ ID NO: 8, the amino acid sequence of the β chain is shown in SEQ ID NO: 10, and the amino acid sequence of the γ chain is shown in SEQ ID NO:
12.
2. The coagulation factor X activating enzyme according to claim 1, characterized in that The α, β and / or γ polypeptide chains are modified with glycosylation.
3. The coagulation factor X activating enzyme according to claim 2, characterized in that At least one amino acid residue of the amino acid sequence of the α, β and / or γ polypeptide chain is covalently linked to an N-glycan.
4. The coagulation factor X activating enzyme according to claim 3, characterized in that The amino acid residue is an asparagine (Asn) residue.
5. The coagulation factor X activating enzyme according to claim 4, characterized in that The asparagine (Asn) residue site is selected from one or more of the following: α chain: Asn28, Asn69, Asn163, Asn183; β chain: Asn59; and / or γ chain: Asn24.
6. The coagulation factor X activating enzyme according to claim 5, characterized in that N-glycans at Asn28 in the α chain include: A2BG2S2, FA2BG2S2, F2A2BG2S2, and A3BG3S3; and / or, N-glycans at Asn69 in the α chain include: FA2S2, A2S2, FA3G2S2, A3G2S2, A4G3S3, and A3S3; and / or, N-glycans at Asn163 in the α chain include: FA2G2S2, A2BG2S2, FA2BG2S2, F2A2BG2S2, A3G3S3, FA3G3S3, A3BG3S3, and FA3BG3S3; and / or, N-glycans at Asn183 in the α chain include: A2G2S1, A2G2S1M4, A2BG1S1, FA2BG1S1, A2BG2S2, FA2BG2S2, and M5; and / or, The N-glycans at the Asn59 position in the β chain include: A2BG2S2, FA2BG2S2, F2A2BG2S2, A3BG3S3, and further include N-glycans with galactose at the end. Preferably, the N-glycans with galactose at the end include: A2BG2S1, FA3G3S2, etc.; and / or, The N-glycans at the Asn24 site in the γ chain include: A2BG1S1, FA2BG1S1, FA2BG2S1, A2BG2S2, FA2BG2S2, F2A2BG2S2, and further include tri-antennary or tetra-antennary branched N-glycans with fucosyl and / or acetylated sialic acid. Preferably, the tri-antennary or tetra-antennary branched N-glycans include FA3G3S2, FA3BG3S3, A3BG2S2, A3BG3S3, etc.
7. The coagulation factor X activating enzyme according to claim 6, characterized in that The N-glycans at Asn28 in the α chain include: A2BG2S2, its relative content is 22-32%, preferably 25-30%, FA2BG2S2, the relative content of which is 30-40%, preferably 34-38%, F2A2BG2S2, the relative content of which is 18-28%, preferably 20-25%, and A3BG3S3, its relative content is 5-10%, preferably 6-9%; and / or, The N-glycans at Asn69 in the α chain include: FA2S2, the relative content of which is 5-10%, preferably 6-9%, A2S2, its relative content is 5-10%, preferably 6-8%, FA3G2S2, the relative content of which is 7-20%, preferably 9-15%, A3G2S2, its relative content is 20-30%, preferably 22-29%, A4G3S3, the relative content of which is 10-25%, preferably 15-20%, and A3S3, its relative content is 15-30%, preferably 16-20%; and / or, The N-glycans at Asn163 in the α chain include: FA2G2S2, the relative content of which is 3-8%, preferably 4-6%, A2BG2S2, its relative content is 6-12%, preferably 8-10%, FA2BG2S2, the relative content of which is 15-25%, preferably 19-22%, F2A2BG2S2, its relative content is 10-25%, preferably 15-20%, A3G3S3, its relative content is 5-10%, preferably 7-9%, FA3G3S3, the relative content of which is 5-10%, preferably 8-9%, A3BG3S3, the relative content of which is 5-10%, preferably 7-9%, and FA3BG3S3, the relative content of which is 3-10%, preferably 5-8%; and / or, The N-glycans at Asn183 in the α chain include: A2G2S1, its relative content is 5-15%, preferably 9-10%, A2G2S1M4, its relative content is 4-8%, preferably 5-6%, A2BG1S1, its relative content is 10-17%, preferably 12-14%, FA2BG1S1, its relative content is 5-10%, preferably 7-8%, A2BG2S2, its relative content is 10-20%, preferably 14-16%, FA2BG2S2, the relative content of which is 6-12%, preferably 8-10%, and M5, its relative content is 3-8%, preferably 4-7%; and / or, The N-glycans at Asn59 in the β chain include: A2BG2S2, its relative content is 15-25%, preferably 19-24%, FA2BG2S2, the relative content of which is 30-40%, preferably 32-34%, F2A2BG2S2, its relative content is 20-30%, preferably 21-27%, A3BG3S3, its relative content is 3-10%; preferably 5-7%, N-glycans with galactose terminal end, the relative content of which is 1-5%, preferably 2-4%; and / or, The N-glycans at Asn24 in the γ chain include: A2BG1S1, its relative content is 4-10%, preferably 6-8%, FA2BG1S1, its relative content is 20-30%, preferably 24-28%, FA2BG2S1, its relative content is 3-8%, preferably 5-7%, A2BG2S2, its relative content is 9-18%, preferably 11-14%, FA2BG2S2, the relative content of which is 20-30%, preferably 25-28%, F2A2BG2S2, its relative content is 4-10%, preferably 6-8%, tri-antennary or tetra-antennary branched N-glycans with fucosyl and acetylated sialic acid, with a relative content of 5-12%, preferably 6-10%; The relative content of N-glycan refers to the percentage of factor X activating enzyme molecules containing a specific N-glycan at a certain site to the total number of factor X activating enzyme molecules.
8. The factor X activating enzyme according to any one of claims 1 to 7, characterized in that The coagulation factor X activating enzyme is derived from Daboia russelii siamensis; preferably, the coagulation factor X activating enzyme is extracted from the venom of Daboia russelii siamensis, or obtained through genetic engineering methods.
9. A pharmaceutical composition, characterized in that The composition comprises the coagulation factor X activating enzyme according to any one of claims 1 to 8, and a pharmaceutically acceptable carrier.
10. A method for stopping bleeding or treating a bleeding disease, characterized in that: The method comprises administering a therapeutically effective amount of the factor X activating enzyme of any one of claims 1 to 8 or the pharmaceutical composition of claim 9 to an individual in need thereof.
11. Use of the factor X activating enzyme according to any one of claims 1 to 8 or the pharmaceutical composition according to claim 8 in the preparation of a medicament for stopping bleeding or treating bleeding diseases.
12. The method according to claim 10 or the use according to claim 11, characterized in that The bleeding diseases include surgical wound bleeding, medical bleeding diseases, hereditary bleeding diseases or coagulation system diseases; preferably, the coagulation system diseases include hemophilia; further preferably, the hemophilia is hemophilia with inhibitors; further preferably, the hemophilia is hemophilia A or hemophilia B.
13. An isolated nucleic acid molecule encoding the factor X activating enzyme of any one of claims 1 to 8.
14. A vector comprising the nucleic acid molecule of claim 13.
15. An isolated host cell, characterized in that The host cell comprises the coagulation factor X activating enzyme according to any one of claims 1 to 8, the nucleic acid molecule according to claim 13, or the vector according to claim 14.
16. A method for preparing the coagulation factor X activating enzyme according to any one of claims 1 to 8, characterized in that: The method comprises the following steps: a) culturing the host cell according to claim 15 under conditions that effectively express factor X activating enzyme; b) obtaining the expressed factor X activating enzyme from the host cells.
17. A method for glycosylation modification of the factor X activating enzyme according to any one of claims 1 to 8, characterized in that: The method comprises genetically engineering a host cell to enable it to produce a coagulation factor X activating enzyme with a predetermined N-glycosylation modification, and / or treating the coagulation factor X activating enzyme with a glycosylation-related enzyme to enable it to have a predetermined N-glycosylation modification.
18. A method for preparing the coagulation factor X activating enzyme according to any one of claims 1 to 8, characterized in that: The method comprises the following steps: a) obtaining a stock solution of Vipera venom; b) separating, purifying, and extracting the snake venom stock solution to obtain the coagulation factor X activating enzyme according to any one of claims 1 to 8.
19. A method for extracting factor X activating enzyme from Vipera rotundus, characterized in that: The method comprises the following steps in sequence: (a) obtaining a sample of Vipera viper venom; (b) subjecting the sample to anion exchange chromatography; (c) After the anion exchange chromatography purification is completed, the sample is subjected to cation exchange chromatography; (d) Obtaining factor X activating enzyme.
20. The method according to claim 19, characterized in that The anion exchange chromatography and cation exchange chromatography are both performed only once.
21. The method according to claim 19 or 20, characterized in that The cation exchange chromatography is not followed by any other purification steps, or the cation exchange chromatography is further followed by a molecular sieve chromatography step and no other purification steps are performed.
22. The method according to any one of claims 19 to 21, characterized in that The chromatographic column filler medium of the anion exchange chromatography is agarose or polymer; Preferably, the chromatography column with agarose as filler is selected from Sepharose HP, Sepharose FF, Capto, or Diamond, more preferably Q Sepharose HP, Q Sepharose FF, Capto Q, EDAE-Sepharose FF, Diamond Q or Diamond MIX-A; Preferably, the filler is a polymer medium such as polystyrene / phenylene divinyl, polyacrylate or diethylaminoethyl; preferably, the chromatography column with the filler being a polymer medium is NenoGel 50 Q, UniGel 65 Q HC or UniGel 30DEAE.
23. The method according to any one of claims 19 to 22, characterized in that: The eluent for the anion exchange chromatography is a Tris-HCl buffer containing NaCl and having a pH value of 8.0-8.6, wherein the concentration of the Tris-HCl buffer is 10 mM-30 mM and the concentration of NaCl is 0.1 M-0.5 M; Preferably, the pH value of the Tris-HCl buffer is 8.5, the concentration of the Tris-HCl buffer is 20 mM, and the concentration of NaCl is 0.4 M; Preferably, the elution flow rate of the anion exchange column chromatography is 30 cm / hour to 150 cm / hour, preferably 80 cm / hour to 120 cm / hour, more preferably 90 cm / hour.
24. The method according to any one of claims 19 to 23, characterized in that The chromatographic column filler medium of the cation exchange chromatography is agarose or polymer; Preferably, the chromatography column whose filler medium is agarose is selected from Capto SP ImpRes, CM Beads 6FF or Diamond MMC; Preferably, the polymer medium is polystyrene / styrene divinyl; preferably, the chromatography column with polymer filler is NenoGel 50 SP.
25. The method according to any one of claims 19 to 24, characterized in that The cation exchange chromatography eluent is a phosphate buffer containing NaCl with a pH value of 6.5-7.5, wherein the concentration of the phosphate buffer is 10mM-30mM and the concentration of NaCl is 0.2M-0.6M; Preferably, the pH value of the phosphate buffer is 6.8, the concentration of the phosphate buffer is 10 mM, and the concentration of NaCl is 0.4 M; Preferably, the elution flow rate of the cation exchange column chromatography is 30 cm / hour to 150 cm / hour, preferably 40 cm / hour to 100 cm / hour, more preferably 60 cm / hour.
26. The method according to any one of claims 19 to 25, characterized in that: Before the anion exchange chromatography, it further comprises molecular sieve chromatography, heparin affinity chromatography and / or hydrophobic chromatography.
27. The method according to claim 26, characterized in that The molecular sieve chromatography column filler is selected from gel filtration media, preferably Sephacryl, Superdex or Sephadex; more preferably Sephacryl S-200HR, Superdex75pg, Superdex200pg or SephadexG25; Preferably, the eluent of the molecular sieve is a Tris-HCl buffer with a pH value of 8.0-8.6, and a concentration of the Tris-HCl buffer is 10 mM-30 mM; preferably, the pH value of the Tris-HCl buffer is 8.5, and the concentration is 20 mM; Preferably, the elution flow rate of the molecular sieve chromatography is 30 cm / hour to 150 cm / hour, preferably 40 cm / hour to 120 cm / hour, more preferably 60 cm / hour.
28. The method according to claim 26, characterized in that The chromatographic column filler for heparin affinity chromatography is selected from agarose medium; preferably Capto heparin, Heparin Berpharose FF, Heparin Sepharose 6F.F., Heparin Sepharose HP; Preferably, the eluent of the heparin affinity chromatography is a Tris-HCl buffer containing NaCl with a pH value of 7.6-8.4, wherein the concentration of the Tris-HCl buffer is 10 mM-30 mM and the concentration of NaCl is 0.5 M-1.5 M; Preferably, the pH value of the Tris-HCl buffer is 8.0, the concentration of the Tris-HCl buffer is 20 mM, and the concentration of NaCl is 1.0 M; Preferably, the elution flow rate of the heparin affinity chromatography is 30 cm / hour to 150 cm / hour, preferably 40 cm / hour to 120 cm / hour, and more preferably 60 cm / hour.
29. The method according to claim 26, characterized in that The chromatographic column filler for hydrophobic chromatography is selected from agarose medium; preferably Butyl Bestarose HP; Preferably, the eluent for the hydrophobic chromatography is a phosphate buffer containing NaCl with a pH value of 6.5-7.5, wherein the concentration of the phosphate buffer is 10 mM-30 mM and the concentration of NaCl is 0.5 M-2.5 M; Preferably, the pH value of the phosphate buffer is 7.0, the concentration of the phosphate buffer is 20 mM, and the concentration of NaCl is 1.0 M; Preferably, the elution flow rate of the hydrophobic chromatography is 30 cm / hour to 150 cm / hour, preferably 40 cm / hour to 120 cm / hour, more preferably 60 cm / hour.
30. The method according to any one of claims 19 to 29, characterized in that After the cation exchange chromatography, it further comprises molecular sieve chromatography; Preferably, the filler of the molecular sieve chromatography is selected from gel filtration media, preferably Sephacryl, Superdex or Sephadex; more preferably Sephacryl S-200HR, Superdex75pg, Superdex200pg or SephadexG25. Preferably, the eluent for the molecular sieve chromatography is a phosphate buffer with a pH value of 6.5-7.5 and a concentration of 40 mM-80 mM; more preferably, the phosphate buffer has a pH value of 6.8 and a concentration of 50 mM; Preferably, the elution flow rate of the molecular sieve chromatography is 5 cm / hour to 80 cm / hour, preferably 10 cm / hour to 35 cm / hour. hour, more preferably 20 cm / hour.
31. The method according to any one of claims 19 to 30, characterized in that After the anion exchange chromatography and before the cation exchange chromatography, an ultrafiltration step is also included; Preferably, the specific steps of the ultrafiltration are: collecting the components corresponding to the target peak of the anion exchange chromatography and concentrating them 5-20 times with an ultrafiltration membrane, and then replacing the solution containing the components corresponding to the target peak with 10mM-30mM phosphate buffer, the pH value of the phosphate buffer is 6.5-7.5, and the molecular weight cutoff of the ultrafiltration membrane is 10kD-50kD; More preferably, the concentration of the phosphate buffer is 20 mM, the pH value is 6.8, the molecular weight cut-off of the ultrafiltration membrane is 30 kD, and the concentration multiple is 10 times.
32. The method according to any one of claims 19 to 31, characterized in that After obtaining the snake venom raw material liquid sample and before performing anion chromatography purification, the method further includes a step of performing virus inactivation treatment on the snake venom raw material liquid; preferably, the virus inactivation treatment is performed by S / D method.
33. The method according to any one of claims 19 to 32, characterized in that The coagulation factor X activating enzyme is the coagulation factor X activating enzyme according to any one of claims 1 to 8.
